Thu, Apr 17, 2014, 3:57 AM EDT - U.S. Markets open in 5 hrs 33 mins

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • swhitemd50 swhitemd50 Nov 27, 2012 4:32 PM Flag

    GILDreport

    Gild's 78% SVR in GT 2 & GT 3 hep C is obviously a poor result in this easy to treat group of patients. It is really not any better than interferon/ribavirin but somehow they are able to spin this into being a great result. It will be interesting to see what they say when they release their failing SVR12 results for Sofosbuvir/ribavirin in GT 1 hep C.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • All remaining patients, 22% = 100 - 78%, relapsed after the treatment is over. I am certain that the SVR12 is NOT a cure, and there would be more relapsers when the SVR24 or SVR48 is measured. The 12 wk 7977/RVB regimen is not viable except for the people who cannot tolerate peg/RBV.

      • 1 Reply to thirdmeinvestor
      • Sorry, but the science overwhelmingly supports SVR12. The support was validated during the approval of both PIs actually. 22% relapse would be terrible if the SVR was 50%... but if everyone who doesn't hit SVR relapses.. that is actually pretty good. It just means the virus was nearly eradicated but there was not quite enough drug pressure to do so. If there was say 12% relapse, but 10% failure on-treatment, it would be worse... that would mean the virus is escaping despite constant pressure. 12 weeks is very close here and actually viable for more than just PR intolerant folks. I have no skin in this now... just know the science too well to see these statements that could be misleading to people. I am sure it was not ill-intentioned. It is a complex beast.

    • I think you are missing the point... this is for GT2 / GT3 patients where the logistics of administering interferon is well nigh impossible - so even a probable success rate with an all oral treatment in areas where GT2/GT3 exists is a big deal.

 
VRTX
64.39+1.14(+1.80%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.